愛美客(300896.SZ):引進韓國Huons BP肉毒素產品
格隆匯5月23日丨愛美客(300896.SZ)公佈,於2022年5月20日,公司與韓國Huons BP簽訂經銷合作框架協議,約定公司以研發註冊方式引進Huons BP的肉毒素產品,並在約定經銷區域(指中國,包括澳門和香港)內作為後者指定的唯一合法經銷商進行產品的進口和經銷,公司須獲取協議項下產品的進口和銷售許可證,產品的進口和經銷須以公司在經營區域內取得產品註冊證為前提。
公司表示,該協議的簽署,通過引進海外生物醫藥品種,豐富公司在醫美行業的產品類型,鞏固和保持公司的行業領先地位。此外,利用公司產品註冊經驗和較為完善的營銷體系的優勢,與公司現有醫療器械產品相互協同,提供更完善的醫療美容產品供應,與公司現有醫美產品相互協同,滿足日益多元化的市場需求,提升品牌影響力和核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.